Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Reboxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 12/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reboxetine SCHEMBL3185555 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL6737649 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL1694154 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL13631332 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL1694155 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL5783865 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Esreboxetine SCHEMBL34534 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL3195078 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL3185550 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 | |
| Reboxetine SCHEMBL29930185 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3MLNRADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13767 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122036734-A | Continuous flow preparation method of reboxetine precursor and reboxetine | 上海上药第一生化药业有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122010951-A | New preparation method of reboxetine | 上海上药第一生化药业有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | claimed |
| WO-1999055338-A1 | TREATMENT OF DEPRESSION AND PHARMACEUTICAL PREPARATIONS THEREFOR | SCARISTA LIMITED (GB) | 1999-11-04 | — | — | WO | claimed |
| WO-1999052531-A1 | NEW TREATMENTS FOR NERVOUS DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999052518-A2 | NEW TREATMENTS FOR NERVOUS DISORDERS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-10-21 | — | — | WO | claimed |
| EP-0919236-A1 | Use of a norepinephrine uptake inhibitor for the treatment of oppositional defiant disorder | ELI LILLY AND COMPANY (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0919235-A1 | Use of a norepinephrine reuptake inhibitor for the treatment of conduct disorder | ELI LILLY AND COMPANY (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0909561-A2 | Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder | ELI LILLY AND COMPANY (US) | 1999-04-21 | — | — | EP | claimed |
| WO-1999015176-A1 | TREATMENT OF OPPOSITIONAL DEFIANT DISORDER | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| WO-1999015177-A1 | TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| WO-1999015163-A1 | TREATMENT OF CONDUCT DISORDER | ELI LILLY AND COMPANY (US) | 1999-04-01 | — | — | WO | claimed |
| WO-1999011208-A1 | METHOD AND COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF PHARMACOLOGIC AGENTS | WILLIAMS C DONALD (US) | 1999-03-11 | — | — | WO | claimed |